| Product Code: ETC10765317 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Pembrolizumab Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Pembrolizumab Market Revenues & Volume, 2021 & 2031F |
3.3 China Pembrolizumab Market - Industry Life Cycle |
3.4 China Pembrolizumab Market - Porter's Five Forces |
3.5 China Pembrolizumab Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 China Pembrolizumab Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 China Pembrolizumab Market Revenues & Volume Share, By Combination Therapy, 2021 & 2031F |
3.8 China Pembrolizumab Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 China Pembrolizumab Market Revenues & Volume Share, By Administration Route, 2021 & 2031F |
4 China Pembrolizumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in China |
4.2.2 Rising adoption of immunotherapy treatments in the country |
4.2.3 Government initiatives to improve access to advanced cancer treatments |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in China |
4.3.2 High cost of pembrolizumab treatment |
4.3.3 Limited awareness and education about immunotherapy among healthcare providers and patients in China |
5 China Pembrolizumab Market Trends |
6 China Pembrolizumab Market, By Types |
6.1 China Pembrolizumab Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 China Pembrolizumab Market Revenues & Volume, By Indication, 2021 - 2031F |
6.1.3 China Pembrolizumab Market Revenues & Volume, By Non-Small Cell Lung Cancer, 2021 - 2031F |
6.1.4 China Pembrolizumab Market Revenues & Volume, By Melanoma, 2021 - 2031F |
6.1.5 China Pembrolizumab Market Revenues & Volume, By Head and Neck Cancer, 2021 - 2031F |
6.1.6 China Pembrolizumab Market Revenues & Volume, By Bladder Cancer, 2021 - 2031F |
6.1.7 China Pembrolizumab Market Revenues & Volume, By Hodgkins Lymphoma, 2021 - 2031F |
6.2 China Pembrolizumab Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 China Pembrolizumab Market Revenues & Volume, By PD-1 Inhibitor, 2021 - 2031F |
6.2.3 China Pembrolizumab Market Revenues & Volume, By Immune Checkpoint Blockade, 2021 - 2031F |
6.2.4 China Pembrolizumab Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.2.5 China Pembrolizumab Market Revenues & Volume, By Antibody-Based Therapy, 2021 - 2031F |
6.2.6 China Pembrolizumab Market Revenues & Volume, By Tumor Microenvironment Modulation, 2021 - 2031F |
6.3 China Pembrolizumab Market, By Combination Therapy |
6.3.1 Overview and Analysis |
6.3.2 China Pembrolizumab Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.3.3 China Pembrolizumab Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.3.4 China Pembrolizumab Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.3.5 China Pembrolizumab Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.3.6 China Pembrolizumab Market Revenues & Volume, By Personalized Medicine, 2021 - 2031F |
6.4 China Pembrolizumab Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 China Pembrolizumab Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 China Pembrolizumab Market Revenues & Volume, By Oncology Clinics, 2021 - 2031F |
6.4.4 China Pembrolizumab Market Revenues & Volume, By Specialty Clinics, 2021 - 2031F |
6.4.5 China Pembrolizumab Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.4.6 China Pembrolizumab Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5 China Pembrolizumab Market, By Administration Route |
6.5.1 Overview and Analysis |
6.5.2 China Pembrolizumab Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.5.3 China Pembrolizumab Market Revenues & Volume, By Injection, 2021 - 2031F |
6.5.4 China Pembrolizumab Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.5.5 China Pembrolizumab Market Revenues & Volume, By Hospital Pharmacy, 2021 - 2031F |
6.5.6 China Pembrolizumab Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
7 China Pembrolizumab Market Import-Export Trade Statistics |
7.1 China Pembrolizumab Market Export to Major Countries |
7.2 China Pembrolizumab Market Imports from Major Countries |
8 China Pembrolizumab Market Key Performance Indicators |
8.1 Number of clinical trials involving pembrolizumab in China |
8.2 Percentage of cancer patients receiving immunotherapy treatment |
8.3 Rate of reimbursement for pembrolizumab treatment by health insurance providers in China |
9 China Pembrolizumab Market - Opportunity Assessment |
9.1 China Pembrolizumab Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 China Pembrolizumab Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 China Pembrolizumab Market Opportunity Assessment, By Combination Therapy, 2021 & 2031F |
9.4 China Pembrolizumab Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 China Pembrolizumab Market Opportunity Assessment, By Administration Route, 2021 & 2031F |
10 China Pembrolizumab Market - Competitive Landscape |
10.1 China Pembrolizumab Market Revenue Share, By Companies, 2024 |
10.2 China Pembrolizumab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here